{"title_page": "Vepalimomab", "text_new": "{{Drugbox\n| Verifiedfields = changed\n| verifiedrevid = 470629578\n| image =  \n<!-- Monoclonal antibody data -->\n| type = mab\n| mab_type = mab\n| source = o\n| target = [[Vascular adhesion protein|VAP-1]]\n<!-- Clinical data -->\n| tradename =  \n| pregnancy_AU =  \n| pregnancy_US =  \n| pregnancy_category =  \n| legal_AU =  \n| legal_CA =  \n| legal_UK =  \n| legal_US =  \n| legal_status =  \n| routes_of_administration =  \n<!-- Pharmacokinetic data -->\n| bioavailability =  \n| protein_bound =  \n| metabolism =  \n| elimination_half-life =  \n| excretion =  \n<!-- Identifiers -->\n| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}\n| ChemSpiderID = none\n| CAS_number_Ref = {{cascite|changed|??}}\n| CAS_number = 195158-85-1\n| UNII_Ref = {{fdacite|correct|FDA}}\n| UNII = 0M19J59UH4\n| ATC_prefix = none\n| ATC_suffix =  \n| PubChem =  \n| DrugBank_Ref = {{drugbankcite|correct|drugbank}}\n| DrugBank =  \n<!-- Chemical data -->\n| chemical_formula =  \n| molecular_weight =  \n}}\n'''Vepalimomab''' is an experimental [[mouse]] [[monoclonal antibody]] intended for the treatment of [[inflammation]]s. It blocks [[vascular adhesion protein 1]].<ref>{{cite journal | vauthors = Vainio PJ, Kortekangas-Savolainen O, Mikkola JH, Jaakkola K, Kalimo K, Jalkanen S, Veromaa T | title = Safety of blocking vascular adhesion protein-1 in patients with contact dermatitis | journal = Basic & Clinical Pharmacology & Toxicology | volume = 96 | issue = 6 | pages = 429\u201335 | date = June 2005 | pmid = 15910406 | doi = 10.1111/j.1742-7843.2005.pto_05.x }}</ref> Development of the drug was discontinued in 2002.<ref>{{cite web |title=Vepalimomab | work = AdisInsight |url=https://adisinsight.springer.com/drugs/800016990 | publisher = Springer Nature Switzerland AG }}</ref>\n\n== References ==\n{{reflist}}\n\n{{immunosuppressants}}\n{{Monoclonals for immune system}}\n\n[[Category:Monoclonal antibodies]]\n[[Category:Abandoned drugs]]\n\n{{monoclonal-antibody-stub}}\n{{antineoplastic-drug-stub}}\n", "text_old": "{{Drugbox\n| Verifiedfields = changed\n| verifiedrevid = 470629578\n| image =  \n<!-- Monoclonal antibody data -->\n| type = mab\n| mab_type = mab\n| source = o\n| target = [[Vascular adhesion protein|VAP-1]]\n<!-- Clinical data -->\n| tradename =  \n| pregnancy_AU =  \n| pregnancy_US =  \n| pregnancy_category =  \n| legal_AU =  \n| legal_CA =  \n| legal_UK =  \n| legal_US =  \n| legal_status =  \n| routes_of_administration =  \n<!-- Pharmacokinetic data -->\n| bioavailability =  \n| protein_bound =  \n| metabolism =  \n| elimination_half-life =  \n| excretion =  \n<!-- Identifiers -->\n| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}\n| ChemSpiderID = none\n| CAS_number_Ref = {{cascite|changed|??}}\n| CAS_number = 195158-85-1\n| ATC_prefix = none\n| ATC_suffix =  \n| PubChem =  \n| DrugBank_Ref = {{drugbankcite|correct|drugbank}}\n| DrugBank =  \n<!-- Chemical data -->\n| chemical_formula =  \n| molecular_weight =  \n}}\n'''Vepalimomab''' is an experimental [[mouse]] [[monoclonal antibody]] intended for the treatment of [[inflammation]]s. It blocks [[vascular adhesion protein 1]].<ref>{{cite journal | vauthors = Vainio PJ, Kortekangas-Savolainen O, Mikkola JH, Jaakkola K, Kalimo K, Jalkanen S, Veromaa T | title = Safety of blocking vascular adhesion protein-1 in patients with contact dermatitis | journal = Basic & Clinical Pharmacology & Toxicology | volume = 96 | issue = 6 | pages = 429\u201335 | date = June 2005 | pmid = 15910406 | doi = 10.1111/j.1742-7843.2005.pto_05.x }}</ref> Development of the drug was discontinued in 2002.<ref>{{cite web |title=Vepalimomab | work = AdisInsight |url=https://adisinsight.springer.com/drugs/800016990 | publisher = Springer Nature Switzerland AG }}</ref>\n\n== References ==\n{{reflist}}\n\n{{immunosuppressants}}\n{{Monoclonals for immune system}}\n\n[[Category:Monoclonal antibodies]]\n[[Category:Abandoned drugs]]\n\n{{monoclonal-antibody-stub}}\n{{antineoplastic-drug-stub}}\n", "name_user": "Fswitzer4", "label": "safe", "comment": "added FDA UNII to drug box", "url_page": "//en.wikipedia.org/wiki/Vepalimomab"}
